South Africa has put its rollout of the Oxford-AstraZeneca vaccine on hold after a study showed "disappointing" results against its new Covid variant. Scientists say the variant accounts for 90% ...

Experts are still hopeful that the AstraZeneca vaccine will still be effective at preventing severe cases South Africa's decision to halt its rollout of the Oxford-AstraZeneca vaccine after a ...

South Africa recently received 1 million doses of AstraZeneca-Oxford COVID-19 vaccine and was poised to start vaccinating healthcare workers, but yesterday, health officials announced a pause for the ...

In South Africa and Kenya, AstraZeneca also maintained the status as a Top Employer for the fourth consecutive year and has also been awarded the Best Places to Work certification in Ivory Coast ...

Developers of the Oxford-AstraZeneca vaccine expect to have a modified jab to cope with the South Africa coronavirus variant by autumn, the vaccine’s lead researcher said Sunday. Health ...

After a decade at the helm of the country’s primary health research funder, Professor Glenda Gray will focus again on doing ...

South Africa’s regulator granted the health department permission to distribute the vaccine from AstraZeneca Plc and the University of Oxford in its first nod for Covid-19 inoculations.The ...

That came after the trial data raised concerns about the AstraZeneca vaccine’s effectiveness on mild symptoms from the more infectious 501Y.V2 variant of the virus dominant in South Africa ...

The F.D.A. authorized AstraZeneca’s treatment to be given outside a health care setting, although it will still need a ...

Oxford/AstraZeneca vaccine has been found to be ... of coronavirus just like SARS-CoV-2 and was first reported from South Africa. According to the researchers, this new variant contains 46 ...

Global biopharmaceutical company, AstraZeneca is set to investigate the effectiveness of using artificial intelligence for heart screening.

(IN BRIEF) AstraZeneca’s Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA), a rare immune-mediated vasculitis that can be ...